유럽 ​​심부뇌자극기기 시장 – 2023-2030

Europe Deep Brain Stimulation Devices Market - 2023-2030

상품코드DMMD6262
발행기관DataM Intelligence
발행일2023.02.14
페이지 수200 Pages
포맷PDF + EXCEL
커버리지Europe

₩5,625,000 – ₩10,875,000

보고서 요약(국문)

시장 개요
유럽 심부뇌자극기 시장 규모는 2022년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 XX%입니다.
심부뇌자극(DBS)은 특정 뇌 부위에 미세한 전류를 전달하는 시술입니다. 이 전류는 해당 부위의 뇌세포를 활성화시켜 다양한 질환을 개선하는 데 도움을 줄 수 있습니다. 전류는 피부 아래 쇄골 주변에 이식된 작은 장치에 연결된 하나 이상의 케이블을 통해 뇌로 전달됩니다. 운동 이상, 정신 건강 문제, 간질 등은 DBS로 치료할 수 있는 질환의 일부입니다.
시장 동향
유럽 심부뇌자극기 시장 성장을 견인하는 주요 요인은 심부뇌자극 관련 제품에 대한 수요 증가, 신경 질환 발병률 증가, 그리고 새로운 기기의 지속적인 승인 및 출시입니다.
심부뇌자극 관련 제품에 대한 수요 증가는 시장 성장을 주도할 것으로 예상됩니다.

파킨슨병, 본태성 떨림, 근긴장 이상, 간질과 같은 신경계 질환의 발병률 증가는 중요한 시장 성장 동력입니다. EU에서 신경계 질환은 장애 및 조기 사망의 세 번째로 흔한 원인입니다. 유럽 인구의 고령화가 진행됨에 따라 이러한 질환의 발생 빈도와 부담이 모두 증가할 가능성이 높습니다. 보건 당국은 예방 및 치료에 있어 신경계 질환에 더욱 주의를 기울여야 합니다.
예를 들어, 유럽 파킨슨병 협회는 파킨슨병이 개인마다 증상이 다르게 나타나는 매우 개별적인 질환이므로 맞춤형 치료 및 관리가 필요하다고 주장합니다. 현재 유럽에서 120만 명 이상이 파킨슨병을 앓고 있으며, 2030년에는 그 수가 세 배로 증가할 것으로 예상됩니다. 파킨슨병 유병률이 전 세계적으로 증가하고 있으며 향후 20년 동안 두 배로 증가할 것(60세 이상 인구의 최대 2%, 80세 이상 인구의 최대 6%에 영향을 미침)이라는 점은 우려스러운 부분입니다.

유럽에서 파킨슨병 환자 1인당 평균 비용은 약 11,000유로입니다. 이는 유럽 전체에 연간 139억 유로의 비용을 초래합니다. 질병이 악화될수록 1인당 연간 비용도 증가하며, 비운동 증상은 입원 및 시설 입소의 주요 원인이 되는데, 이는 파킨슨병 치료 비용 증가의 두 가지 중요한 요인입니다.
장비 가격이 높은 것이 시장 성장을 저해할 것으로 예상됩니다.
하지만 심부뇌자극술(DBS)은 운동 이상을 치료하는 데 사용됩니다. DBS의 비용 효율성을 판단하기 위해서는 최고 수준의 경제성 평가(EE)가 필요합니다. 신경자극기 배터리 교체 비용을 포함한 DBS 치료의 전체 비용은 53,217유로입니다. 이러한 비용 문제는 특히 저개발 국가에서 심각한데, DBS로 치료 가능한 운동 장애 및 기타 질병이 만연함에도 불구하고 장비 및 치료 비용을 감당할 수 있는 사람이 거의 없기 때문입니다. 수술 장비와 지식 부족은 여전히 ​​어려움으로 남아 있지만, 저비용 IPG(이식형 맥박 발생기)가 더욱 발전한다면 이러한 문제는 최소화될 수 있습니다.
COVID-19 영향 분석
심부뇌자극술(DBS) 치료를 받는 파킨슨병(PD) 환자를 포함한 모든 환자는 COVID-19 팬데믹으로 인한 의료 시설 폐쇄의 영향을 받았습니다. 병원들은 COVID-19 환자로 과부하가 걸리면서 초기 DBS 장치 설치 및 배터리 소모된 IPG 교체와 같은 선택적 수술을 연기했습니다. 파킨슨병 환자에게 가장 많이 시행되는 수술은 DBS이며, 유럽에서는 매년 수천 건의 이식 수술이 시행됩니다.
COVID-19 팬데믹은 의료 서비스의 디지털 기술 전환을 가속화했습니다. 헝가리를 포함한 많은 국가들이 원격 의료를 도입했습니다. 헝가리에서 DBS 치료를 받는 약 1,000명의 운동 장애 환자들을 위한 신경학적 치료의 중요한 부분을 마무리하기 위해서는 원격 프로그래밍이 아직 개선되어야 합니다. 원격 프로그래밍은 COVID-19 팬데믹 기간 동안 DBS 치료를 지속하는 빠르고 효과적인 방법임이 이미 입증되었습니다.

애보트는 DBS 기기 제조업체 중 최초로 환자들이 집이나 Wi-Fi 또는 셀룰러 네트워크에 연결된 다른 장소에서 신경과 전문의와 연락하여 DBS 조정을 받을 수 있도록 하는 새로운 기술(뉴로스피어)을 도입했습니다. CE 마크와 미국 식품의약국(FDA) 승인을 받은 후, 이 혁신 기술은 미국 및 영국, 아일랜드, 독일을 포함한 유럽 여러 국가에서 사용되기 시작했습니다.
세그먼트 분석
병원 부문은 예측 기간(2022-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
DBS 기기의 최종 사용자 부문 시장 점유율은 높을 것으로 예상됩니다. 주요 최종 사용자는 신경계 질환 환자에게 최상의 치료를 제공하는 병원입니다. 병원은 우수한 지원, 치료 및 다양한 치료 옵션을 제공합니다. 여러 의사가 협력하여 다양한 치료법을 통합한 포괄적인 치료 계획을 수립합니다. 이러한 다학제 팀은 신경계 질환 환자에게 매우 중요합니다.
신경외과 의사는 시술 중 하나 이상의 전극을 뇌에 삽입합니다. 이러한 리드와 연장선 사이의 연결은 리드와 소형 신경자극기(내부 펄스 발생기)의 전극을 연결합니다. 의사는 신경자극기를 이식한 후 몇 주 후에 전기 신호를 제공하도록 프로그래밍합니다. 신경자극기가 전류를 적절하게 조절하고 효과를 발휘하려면 이 프로그래밍 과정에 주 또는 월 단위로 여러 번 병원을 방문해야 할 수 있습니다. 의사는 장치를 조정하는 동안 부작용을 최소화하고 증상을 개선하는 데 이상적인 균형을 맞추는 데 주의를 기울입니다. 이러한 모든 요소가 시장 성장을 주도합니다.
지역 분석
독일은 유럽 심부뇌자극기 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
독일은 인구가 많고, 우수한 의료 인프라를 갖추고 있으며, 소득 수준이 높기 때문에 유럽 심부뇌자극기 시장을 주도하고 있습니다. 독일 파킨슨병 협회에 따르면 독일에는 약 25만 명의 파킨슨병 환자가 있습니다. 전 세계적으로 8만 명 이상이 심부뇌자극을 이용하고 있으며, 이 중 약 3분의 2가 파킨슨병 환자입니다. 이 장치는 흔히 "뇌 박동기"라고도 불립니다. 심부뇌자극술은 불안, 심각한 우울증, 강박장애 치료에도 사용됩니다.
알츠하이머병이나 투렛 증후군 치료와 같은 다른 분야에서도 임상 시험이 진행 중입니다. 특히 새로운 치료법을 도입할 때는 환자에게 발생할 수 있는 잠재적 위험과 예상치 못한 부작용을 배제하기 위해 영장류를 대상으로 한 사전 연구가 필수적입니다.
이러한 치료법은 뇌 이식과 같은 부작용 없이 인간에게 유익할 수 있습니다. 심부뇌자극술의 정확한 목표 영역은 영장류 뇌의 구조와 기능에 대한 신경과학적 연구를 통해 발견되었습니다. 원숭이를 대상으로 한 연구 결과는 전극 기술과 이식 기술의 기초가 되었습니다. 이러한 시술을 자주 시행하는 프라이부르크 대학 병원에 따르면, 모든 합병증 중 단 2%만이 수술 자체와 관련이 있습니다.

경쟁 환경
심부뇌자극기 시장은 Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, AlevaNeurotherapeutics SA, Functional Neuromodulation Ltd., Cyberonics, Inc, LivaNova PLC, Nevro Corporation 등 국내외 기업들이 진출해 있는 가운데, 경쟁이 비교적 치열한 시장입니다. 주요 기업들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 통해 시장 성장에 기여하고 있습니다. 예를 들어, 의료기기 대기업 Medtronic의 심부뇌자극기 Percept는 2020년 1월 유럽 CE 마크를 획득했습니다. 심부뇌자극은 파킨슨병, 간질, 강박장애(OCD) 등의 증상을 완화하는 데 도움이 되는 전기 신호를 생성하는 잘 알려진 의료 기술입니다.
Abbott Laboratories.

개요: Abbott는 의료기기 및 헬스케어 제품을 개발하는 미국의 다국적 기업입니다. 1888년에 설립되었으며 미국 일리노이주에 본사를 두고 있습니다. 이 회사의 제품 및 서비스에는 의료 기기, 진단 기기, 영양 제품 및 브랜드 제네릭 의약품이 포함됩니다.
제품 포트폴리오:
인피니티 DBS 시스템: 인피니티 DBS는 운동 장애, 파킨슨병, 본태성 떨림과 같은 질환 치료에 사용되는 모든 주요 표적에 대해 승인된 최초의 방향성 DBS 시스템입니다.
유럽 심부뇌자극기 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 200페이지(약) 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The Europe Deep brain stimulation devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).
Deep brain stimulation (DBS) gives a little electrical current to a particular brain region. Several conditions can be helped by the current's electricity, which activates the brain cells there. The current travels to the brain through one or more cables connected to a small implanted device placed beneath the skin and around the collarbone. Movement abnormalities, mental health issues, and epilepsy are just a few of the ailments that DBS can treat.
Market Dynamics
The major factors driving the Europe Deep brain stimulation devices market are increasing demand for products involving deep brain stimulation, the rising incidence of neurological diseases and periodical authorization and introduction of novel devices.
Increasing demand for products involving deep brain stimulation is expected to drive the market’s growth.
A significant market driver is the rising incidence of neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy. In the EU, neurological illnesses are the third most frequent cause of incapacity and early mortality. As the population of Europe ages, it is probable that both their frequency and burden will rise. Health authorities need to pay more attention to neurological illnesses in prevention and treatment.
The European Parkinson's Disease Association, for instance, claims that Parkinson's is a very individual disorder that varies from person to person and necessitates a customized approach to therapy and care. Parkinson's disease affects more than 1.2 million individuals in Europe now, and by 2030, that number is expected to triple. It is concerning that the prevalence of Parkinson's disease is rising globally and that during the next 20 years, it will double (affecting up to 2% of persons over 60 and 6% of those over 80).
In Europe, the average cost per patient with Parkinson's disease is around €11,000. This results in an annual cost to Europe of €13.9 billion. As the condition worsens, the cost per person per year also rises, and non-motor symptoms are a primary cause of hospitalization and institutionalization, two important cost drivers in Parkinson's care.
High cost of equipment will expected to hamper the market’s growth.
However, movement abnormalities are treated by deep brain stimulation (DBS). To determine how cost-effective DBS is, the highest level economic evaluations (EEs) are required. The entire cost of treatment for DBS, including the battery replacement the neurostimulator device requires, is €53,217. The cost issue is particularly problematic in impoverished countries, where few people can afford the hardware and treatment fees, despite the high frequency of movement disorders and other illnesses that can be treated with DBS. The lack of surgical equipment and knowledge may still be a challenge, but if low-cost IPGs develop further, this problem may be minimized.
COVID-19 Impact Analysis
All patients, including those with Parkinson's disease (PD) treated with deep brain stimulation, were adversely affected by COVID-19 pandemic shutdowns (DBS). Hospitals delayed elective operations, including initial DBS device installation and implanted pulse generator (IPG) replacements for exhausted batteries because they were overloaded with COVID-19 cases. The most popular surgical procedure for PD patients is DBS, with thousands of implantations occurring yearly in Europe.
The COVID-19 pandemic has expedited healthcare's transition to digital technology. Many nations, including Hungary, have adopted telemedicine. Teleprogramming has yet to be improved in the cases of the roughly 1000 Hungarian patients with movement MDs treated with DBS to finish the important parts of neurological care. Remote programming has previously been proven to be a quick and effective method for continuing to administer DBS therapy during COVID-19.
Abbott has been the first among DBS device manufacturers to introduce a new technology (NeuroSphere) that enables patients to contact their neurologists and obtain DBS modifications from home or another location with WiFi or cellular access. After receiving the CE mark and Food and Drug Administration approval, this innovation began to be utilized in the United States and other European nations, including the United Kingdom, Ireland, and Germany.
Segment Analysis
Hospitals segment is expected to grow at the fastest CAGR during the forecast period (2022-2030)
The end user segment market share for DBS devices is anticipated to be high. The primary end-user is a hospital since they offer superior care to patients with neurological problems. They offer superior assistance, care, and a range of therapeutic choices. Several doctors typically collaborate to create a comprehensive treatment plan for patients that incorporate a variety of treatments. This interdisciplinary team is of the greatest priority for those with neurological diseases.
Neurosurgeons insert one or more leads during the procedure into the brain. A connection between these leads and an extension wire creates a link between the leads and electrodes of a tiny neurostimulator (internal pulse generator). The doctor programs the neurostimulator to provide electrical signals a few weeks after it is implanted. This programming process may require more than one visit in a week or month for the neurostimulator to appropriately regulate the current and deliver results. While adjusting the device, the doctor is mindful of striking the ideal balance between minimizing the negative effects and enhancing the symptoms. The segments drive the market for all these factors.
Geographical Analysis
Germany holds the largest market share in the Europe Deep brain stimulation devices market.
Germany dominates the Europe Deep brain stimulation devices market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 250,000 people in Germany have Parkinson's disease, according to the German Parkinson Association. Over 80,000 people utilize deep brain stimulation globally, with Parkinson's disease accounting for about two-thirds of users. The device is also known as a "brain pacemaker" in common parlance. Deep brain stimulation also treats anxiety, severe depression, and obsessive-compulsive disorder.
Clinical trials are also undertaken in other fields, such as the treatment of Alzheimer's illness and Tourette syndrome. Previous studies with non-human primates are essential, especially when introducing novel therapeutic techniques, to rule out any potential harm to patients and the emergence of unexpected side effects.
This kind of treatment can benefit humans without having negative effects through brain implantation. Deep brain stimulation's precise target area was discovered through the neuroscientific study of the structure and function of non-human primates' brains. The findings from studies with monkeys also served as the foundation for electrode technology and implantation techniques. According to the Freiburg University Clinic, which frequently performs these procedures, only 2% of all difficulties are related to the surgery itself.
Competitive Landscape
The Deep brain stimulation devices market is moderately competitive with local and Europe companies’ presence Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, AlevaNeurotherapeutics SA, Functional Neuromodulation Ltd., Cyberonics, Inc, LivaNova PLC, Nevro Corporation. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in January 2020, the deep brain stimulation device Percept from the medical technology behemoth Medtronic has just been given the European CE Mark. A well-known medical technique called deep brain stimulation produces electrical signals that can reduce symptoms of Parkinson's disease, epilepsy, OCD, and other diseases.
Abbott Laboratories.
Overview:Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.
Product Portfolio:
Infinity DBS System: Infinity DBS is the first directional DBS system that has been approved for all key targets that are used for treatments like movement disorders, Parkinson's disease and Essential Tremor.
Europe Deep brain stimulation devices market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing demand for products involving deep brain stimulation
4.1.1.2. The rising incidence of neurological diseases
4.1.2. Restraints:
4.1.2.1. The high cost of equipment will restrict the market's expansion.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Single-Channel Deep Brain Stimulator
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Dual-Channel Deep Brain Stimulator
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Parkinson's Disease
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
8.3. Epilepsy
8.4. Essential Tremor
8.5. Dystonia
8.6. Obsessive-Compulsive Disorder
8.7. Others
9. By End user
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Neurological Clinics
9.4. Ambulatory Surgical Centers
10. By Country
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2022-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3. U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.7.4.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Medtronic PLC
12.3. Boston Scientific Corporation
12.4. Renishaw PLC
12.5. AlevaNeurotherapeutics SA
12.6. Functional Neuromodulation Ltd.
12.7. Cyberonics, Inc
12.8. LivaNova PLC
12.9. Nevro Corporation.
LIST NOT EXHAUSTIVE
13. Europe Deep brain stimulation devices Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us

언급된 주요 기업들

Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, AlevaNeurotherapeutics SA, Functional Neuromodulation Ltd., Cyberonics, Inc, LivaNova PLC, Nevro Corporation.

표 목록 (Tables)

List of Tables

Table 1Global Deep Brain Stimulation Devices Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)

Table 2Global Deep Brain Stimulation Devices Market Value, By Application, 2022, 2026 & 2030 ($ Million)

Table 3Global Deep Brain Stimulation Devices Market Value, By End user, 2022, 2026 & 2030 ($ Million)

Table 4Global Deep Brain Stimulation Devices Market Value, By Country, 2022, 2026 & 2030 ($ Million)

Table 5Global Deep Brain Stimulation Devices Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)

Table 6Global Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 7Global Deep Brain Stimulation Devices Market Value, By Application, 2022, 2026 & 2030 ($ Million)

Table 8Global Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 9Global Deep Brain Stimulation Devices Market Value, By End user, 2022, 2026 & 2030 ($ Million)

Table 10Global Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 11Global Deep Brain Stimulation Devices Market Value, By country, 2022, 2026 & 2030 ($ Million)

Table 12Global Deep Brain Stimulation Devices Market Value, By Country, 2021-2030 ($ Million)

Table 13Germany Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 14Germany Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 15Germany Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 16U.K. Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 17U.K. Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 18U.K. Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 19France Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 21France Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 22France Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 23Italy Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 24Italy Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 25Italy Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 26Spain Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 27Spain Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 28Spain Deep Brain Stimulation Devices Market Value, By Product Type, 2021-2030 ($ Million)

Table 29Rest of Europe Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 30Rest of Europe Deep Brain Stimulation Devices Market Value, By Application, 2021-2030 ($ Million)

Table 31Rest of Europe Deep Brain Stimulation Devices Market Value, By End user, 2021-2030 ($ Million)

Table 32Abbott Laboratories: Overview

Table 33Abbott Laboratories: Product Portfolio

Table 34Abbott Laboratories: Key Developments

Table 35Medtronic PLC: Overview

Table 36Medtronic PLC: Product Portfolio

Table 37Medtronic PLC: Key Developments

Table 38Boston Scientific Corporation: Overview

Table 39Boston Scientific Corporation: Product Portfolio

Table 40Boston Scientific Corporation: Key Developments

Table 41Renishaw PLC: Overview

Table 42Renishaw PLC: Product Portfolio

Table 43Renishaw PLC: Key Developments

Table 44AlevaNeurotherapeutics SA: Overview

Table 45AlevaNeurotherapeutics SA: Product Portfolio

Table 46AlevaNeurotherapeutics SA: Key Developments

Table 47Functional Neuromodulation Ltd.: Overview

Table 48Functional Neuromodulation Ltd.: Product Portfolio

Table 49Functional Neuromodulation Ltd.: Key Developments

Table 50Cyberonics, Inc: Overview

Table 51Cyberonics, Inc: Product Portfolio

Table 52Cyberonics, Inc: Key Developments

Table 53LivaNova PLC: Overview

Table 54LivaNova PLC: Product Portfolio

Table 55LivaNova PLC: Key Developments

Table 56Nevro Corporation: Overview

Table 57Nevro Corporation: Product Portfolio

Table 58Nevro Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure1Europe Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure2Europe Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure3Europe Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure4Europe Deep Brain Stimulation Devices Market Share, By Country, 2021 & 2030 (%)

Figure5Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure6Europe Deep Brain Stimulation Devices Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure7Single-Channel Deep Brain Stimulator: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure8Dual-Channel Deep Brain Stimulator: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure9Europe Deep Brain Stimulation Devices Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure10Parkinson's Disease: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure11Epilepsy: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure12Essential Tremor: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure13Dystonia: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure14Obsessive-Compulsive Disorder: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure15Others: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure16Europe Deep Brain Stimulation Devices Market Y-o-Y Growth, By End user, 2022-2030 (%)

Figure17Hospitals: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure18Neurological Clinics: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure19Ambulatory Surgical Centers: Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure20Europe Deep Brain Stimulation Devices Market Y-o-Y Growth, By Country, 2022-2030 (%)

Figure21Germany Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure22Germany Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure23Germany Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure24Germany Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure25Germany Deep Brain Stimulation Devices Market Share, By Country, 2021 & 2030 (%)

Figure26U.K. Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure27U.K. Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure28U.K. Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure29U.K. Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure30U.K. Deep Brain Stimulation Devices Market Share, By Country, 2021 & 2030 (%)

Figure31France Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure32France Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure33France Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure34France Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure35France Deep Brain Stimulation Devices Market Share, By Country, 2021 & 2030 (%)

Figure36Italy Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure37Italy Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure38Italy Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure39Italy Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure40Italy Deep Brain Stimulation Devices Market Share, By Country, 2021 & 2030 (%)

Figure41Spain Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure42Spain Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure43Spain Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure44Spain Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure45Rest of Europe Deep Brain Stimulation Devices Market Value, 2021-2030 ($ Million)

Figure46Rest of Europe Deep Brain Stimulation Devices Market Share, By Product Type, 2021 & 2030 (%)

Figure47Rest of Europe Deep Brain Stimulation Devices Market Share, By Application, 2021 & 2030 (%)

Figure48Rest of Europe Deep Brain Stimulation Devices Market Share, By End user, 2021 & 2030 (%)

Figure49Abbott Laboratories: Financials

Figure50Medtronic PLC: Financials

Figure51Boston Scientific Corporation: Financials

Figure52Renishaw PLC: Financials

Figure53AlevaNeurotherapeutics SA: Financials

Figure54Functional Neuromodulation Ltd.: Financials

Figure55Cyberonics, Inc: Financials

Figure56LivaNova PLC: Financials

Figure57Nevro Corporation: Financials